Early molecular diagnosis and biological subtyping of the tumour is a crucial component in the overall prospects for more effective therapies. We encourage parents to contact us as soon as their child is diagnosed.
Upon presenting to us, children will typically undergo a biopsy to determine the molecular characteristics of the tumour and to advise the personalized available treatment regimens specific to each individual child’s tumour.
Further, we aim to collect blood and cerebrospinal fluid whenever feasible to integrate novel technologies such as assessment of circulating tumour DNA to better understand changes of the tumour. We believe that the historical reliance on MRI and clinical condition assessment need further integration into emerging technologies to make therapeutic progress.